Structured Review

Bayer AG nifedipine
Displacement by <t>nifedipine</t> of [ 3 H]-R-PIA and [ 3 H]-XAC bound to membrane receptors. Open symbols [ 3 H]-R-PIA binding (K i app. 4.15 ± 1.37 × 10 −6 , B max app. 653 fmol/mg protein); closed symbols [ 3 H]-XAC (K i app. 1.86 ± 0.42 × 10 −6 M, B max app. 868 fmol/mg protein).
Nifedipine, supplied by Bayer AG, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/nifedipine/product/Bayer AG
Average 92 stars, based on 1 article reviews
Price from $9.99 to $1999.99
nifedipine - by Bioz Stars, 2021-01
92/100 stars

Images

1) Product Images from "Interaction of Dihydropyridine Calcium Channel Agonists and Antagonists with Adenosine Receptors"

Article Title: Interaction of Dihydropyridine Calcium Channel Agonists and Antagonists with Adenosine Receptors

Journal: Pharmacology & toxicology

doi:

Displacement by nifedipine of [ 3 H]-R-PIA and [ 3 H]-XAC bound to membrane receptors. Open symbols [ 3 H]-R-PIA binding (K i app. 4.15 ± 1.37 × 10 −6 , B max app. 653 fmol/mg protein); closed symbols [ 3 H]-XAC (K i app. 1.86 ± 0.42 × 10 −6 M, B max app. 868 fmol/mg protein).
Figure Legend Snippet: Displacement by nifedipine of [ 3 H]-R-PIA and [ 3 H]-XAC bound to membrane receptors. Open symbols [ 3 H]-R-PIA binding (K i app. 4.15 ± 1.37 × 10 −6 , B max app. 653 fmol/mg protein); closed symbols [ 3 H]-XAC (K i app. 1.86 ± 0.42 × 10 −6 M, B max app. 868 fmol/mg protein).

Techniques Used: Binding Assay

2) Product Images from "Mineralocorticoid Receptor Blocker Eplerenone Improves Endothelial Function and Inhibits Rho-Associated Kinase Activity in Patients With Hypertension"

Article Title: Mineralocorticoid Receptor Blocker Eplerenone Improves Endothelial Function and Inhibits Rho-Associated Kinase Activity in Patients With Hypertension

Journal: Clinical pharmacology and therapeutics

doi: 10.1038/clpt.2011.227

Representative measurements of the migration of circulating progenitor cells (CPCs) labeled with DAPI by fluorescence in a patient treated with eplerenone, a patient treated with nifedipine, and a patient treated with losartan before the beginning of treatment (0 weeks) and after 4, 12, and 48 weeks of treatment (top). Comparison of the migration of CPCs in patients in the eplerenone, nifedipine, and losartan groups before the beginning of treatment (0 weeks) and after 4, 12, and 48 weeks of treatment (bottom). * P
Figure Legend Snippet: Representative measurements of the migration of circulating progenitor cells (CPCs) labeled with DAPI by fluorescence in a patient treated with eplerenone, a patient treated with nifedipine, and a patient treated with losartan before the beginning of treatment (0 weeks) and after 4, 12, and 48 weeks of treatment (top). Comparison of the migration of CPCs in patients in the eplerenone, nifedipine, and losartan groups before the beginning of treatment (0 weeks) and after 4, 12, and 48 weeks of treatment (bottom). * P

Techniques Used: Migration, Labeling, Fluorescence

Representative measurements of the number of circulating progenitor cells (CPCs) by flow cytometry in a patient treated with eplerenone, a patient treated with nifedipine, and a patient treated with losartan before the beginning of treatment (0 weeks) and after 4, 12, and 48 weeks of treatment (top). Comparison of the number of CPCs in patients in the eplerenone, nifedipine, and losartan groups before the beginning of treatment (0 weeks) and after 4, 12, and 48 weeks of treatment (bottom). * P
Figure Legend Snippet: Representative measurements of the number of circulating progenitor cells (CPCs) by flow cytometry in a patient treated with eplerenone, a patient treated with nifedipine, and a patient treated with losartan before the beginning of treatment (0 weeks) and after 4, 12, and 48 weeks of treatment (top). Comparison of the number of CPCs in patients in the eplerenone, nifedipine, and losartan groups before the beginning of treatment (0 weeks) and after 4, 12, and 48 weeks of treatment (bottom). * P

Techniques Used: Flow Cytometry, Cytometry

Representative data from western blot analysis for phospho-myosin-binding subunit (p-MBS), total-myosin-binding subunit (t-MBS), and β tublin in a patient treated with eplerenone, a patient treated with nifedipine, and a patient treated with losartan before the beginning of treatment (0 weeks) and after 4, 12, and 48 weeks of treatment (top). ROCK activity (p-MBS/t-MBS) in patients in the eplerenone, nifedipine, and losartan groups before the beginning of treatment (0 weeks) and after 4, 12, and 48 weeks of treatment (bottom). * P
Figure Legend Snippet: Representative data from western blot analysis for phospho-myosin-binding subunit (p-MBS), total-myosin-binding subunit (t-MBS), and β tublin in a patient treated with eplerenone, a patient treated with nifedipine, and a patient treated with losartan before the beginning of treatment (0 weeks) and after 4, 12, and 48 weeks of treatment (top). ROCK activity (p-MBS/t-MBS) in patients in the eplerenone, nifedipine, and losartan groups before the beginning of treatment (0 weeks) and after 4, 12, and 48 weeks of treatment (bottom). * P

Techniques Used: Western Blot, Binding Assay, Activity Assay

3) Product Images from "Effects of nicorandil as compared to mixtures of sodium nitroprusside and levcromakalim in isolated rat aorta"

Article Title: Effects of nicorandil as compared to mixtures of sodium nitroprusside and levcromakalim in isolated rat aorta

Journal: British Journal of Pharmacology

doi: 10.1038/sj.bjp.0702375

Correlation between the relative potency of ODQ vs glibenclamide (GLI) to inhibit the relaxant effects of SNP:LEM mixtures and nicorandil (NIC) and the relative potency of SNP vs LEM in different experimental conditions. Ordinate: logarithm of the ratio of the potency of ODQ and GLI expressed as apparent K B . The apparent K B were calculated at the level of 30% relaxation. Abscissa: logarithm of the ratio of the potency of SNP and LEM expressed as IC 30 . The relative potencies (IC 30 (SNP)/IC 30 (LEM)) were 0.038, 0.125 and 0.021 for KCl, NA and NA plus nifedipine, respectively, and these values were corrected for the proportion factor in the mixtures, for the data with NIC these values were artificially set to those of the 1:30 SNP:LEM mixture. The data for the 1:10, 1:30 and 1:100 SNP:LEM mixtures were calculated from previous figures and the data for the 1:1 and 1:1000 are not shown. Since open circles and squares followed a similar trend they were pooled for the regression analysis. Note that data for the 1:30 SNP:LEM mixture fell into the line, while those for NIC did not follow any correlation. Since GLI had no inhibitory action on NIC-induced relaxation in KCl-stimulated arteries, the Log (K B (ODQ)/K B (GLI)) cannot be calculated but has to be smaller than −3.
Figure Legend Snippet: Correlation between the relative potency of ODQ vs glibenclamide (GLI) to inhibit the relaxant effects of SNP:LEM mixtures and nicorandil (NIC) and the relative potency of SNP vs LEM in different experimental conditions. Ordinate: logarithm of the ratio of the potency of ODQ and GLI expressed as apparent K B . The apparent K B were calculated at the level of 30% relaxation. Abscissa: logarithm of the ratio of the potency of SNP and LEM expressed as IC 30 . The relative potencies (IC 30 (SNP)/IC 30 (LEM)) were 0.038, 0.125 and 0.021 for KCl, NA and NA plus nifedipine, respectively, and these values were corrected for the proportion factor in the mixtures, for the data with NIC these values were artificially set to those of the 1:30 SNP:LEM mixture. The data for the 1:10, 1:30 and 1:100 SNP:LEM mixtures were calculated from previous figures and the data for the 1:1 and 1:1000 are not shown. Since open circles and squares followed a similar trend they were pooled for the regression analysis. Note that data for the 1:30 SNP:LEM mixture fell into the line, while those for NIC did not follow any correlation. Since GLI had no inhibitory action on NIC-induced relaxation in KCl-stimulated arteries, the Log (K B (ODQ)/K B (GLI)) cannot be calculated but has to be smaller than −3.

Techniques Used:

4) Product Images from "Nifedipine suppresses neointimal thickening by its inhibitory effect on vascular smooth muscle cell growth via a MEK-ERK pathway coupling with Pyk2"

Article Title: Nifedipine suppresses neointimal thickening by its inhibitory effect on vascular smooth muscle cell growth via a MEK-ERK pathway coupling with Pyk2

Journal: British Journal of Pharmacology

doi: 10.1038/sj.bjp.0703730

Effect of nifedipine on the changes of total cellular protein concentrations in rat VSMC. The results were derived from five separate experiments, and each experiment was performed in triplicate. Each bar represents the mean±s.e.mean. * P
Figure Legend Snippet: Effect of nifedipine on the changes of total cellular protein concentrations in rat VSMC. The results were derived from five separate experiments, and each experiment was performed in triplicate. Each bar represents the mean±s.e.mean. * P

Techniques Used: Derivative Assay

Effect of nifedipine on the phosphorylation and protein level of ERK 1/2 (p44/42) in rat VSMC. (A) The phosphorylation or protein level of ERK 1/2 was detected by immunoblot analysis using antibody phosphospecific or specific for ERK 1/2, as described in Methods. p-ERK 1/2 or ERK 1/2 shows the phosphorylation or the protein level of ERK 1/2, respectively. (B) The quantitation of the phosphorylated ERK 1/2 from three separate experiments is shown, and each bar represents the mean±s.e.mean. * P
Figure Legend Snippet: Effect of nifedipine on the phosphorylation and protein level of ERK 1/2 (p44/42) in rat VSMC. (A) The phosphorylation or protein level of ERK 1/2 was detected by immunoblot analysis using antibody phosphospecific or specific for ERK 1/2, as described in Methods. p-ERK 1/2 or ERK 1/2 shows the phosphorylation or the protein level of ERK 1/2, respectively. (B) The quantitation of the phosphorylated ERK 1/2 from three separate experiments is shown, and each bar represents the mean±s.e.mean. * P

Techniques Used: Quantitation Assay

Effect of nifedipine on the value of I/M ratio from rat left common carotid artery 14 days after balloon catheterization. C: mixtur of ethanol and polyethylen-glycol 400 only ( n =9); L: treatment with 0.3 mg kg −1 day −1 of nifedipine ( n =9); H: treatment with 3 mg kg −1 day −1 of nifedipine ( n =9). Values are the mean±s.e.mean. ** P
Figure Legend Snippet: Effect of nifedipine on the value of I/M ratio from rat left common carotid artery 14 days after balloon catheterization. C: mixtur of ethanol and polyethylen-glycol 400 only ( n =9); L: treatment with 0.3 mg kg −1 day −1 of nifedipine ( n =9); H: treatment with 3 mg kg −1 day −1 of nifedipine ( n =9). Values are the mean±s.e.mean. ** P

Techniques Used:

Cytotoxic effect of nifedipine in VSMC
Figure Legend Snippet: Cytotoxic effect of nifedipine in VSMC

Techniques Used:

Effect of nifedipine on the phosphorylation and protein level of Pyk2 in rat VSMC. (A) The phosphorylation or protein level of Pyk2 was detected by immunoblot analysis using antibody specific for phosphotyrosine (PY20) or for Pyk2, as described in Methods. p-Pyk2 or Pyk2 shows the phosphorylation or protein level of Pyk2, respectively. (B) The quantitation of the phosphorylated Pyk2 from three separate experiments is shown, and each bar represents the mean±s.e.mean. * P
Figure Legend Snippet: Effect of nifedipine on the phosphorylation and protein level of Pyk2 in rat VSMC. (A) The phosphorylation or protein level of Pyk2 was detected by immunoblot analysis using antibody specific for phosphotyrosine (PY20) or for Pyk2, as described in Methods. p-Pyk2 or Pyk2 shows the phosphorylation or protein level of Pyk2, respectively. (B) The quantitation of the phosphorylated Pyk2 from three separate experiments is shown, and each bar represents the mean±s.e.mean. * P

Techniques Used: Quantitation Assay

Effect of nifedipine on DNA synthesis in rat VSMC. The results were derived from five separate experiments, and each experiment was performed in triplicate. Each bar represents the mean±s.e.mean. ** P
Figure Legend Snippet: Effect of nifedipine on DNA synthesis in rat VSMC. The results were derived from five separate experiments, and each experiment was performed in triplicate. Each bar represents the mean±s.e.mean. ** P

Techniques Used: DNA Synthesis, Derivative Assay

Cross-sections of rat left common carotid artery 14 days after balloon catheterization. EM stains (A–C) and immunohistological stainings with anti-SMA antibody and developed by the ABC method (D–F). 0.4 mg ml −1 of DAB was used as the chromogen of the ABC method, and the antibody-positive staining is shown as brown. (A,D) C: mixture of ethanol and polyethylen-glycol 400 only; (B,E) L: treatment with 0.3 mg kg −1 day −1 of nifedipine; (C,F) H: treatment with 3 mg kg −1 day −1 of nifedipine. Arrowheads indicate the position of the internal elastic lamina. The preparations were examined under ×20 magnification.
Figure Legend Snippet: Cross-sections of rat left common carotid artery 14 days after balloon catheterization. EM stains (A–C) and immunohistological stainings with anti-SMA antibody and developed by the ABC method (D–F). 0.4 mg ml −1 of DAB was used as the chromogen of the ABC method, and the antibody-positive staining is shown as brown. (A,D) C: mixture of ethanol and polyethylen-glycol 400 only; (B,E) L: treatment with 0.3 mg kg −1 day −1 of nifedipine; (C,F) H: treatment with 3 mg kg −1 day −1 of nifedipine. Arrowheads indicate the position of the internal elastic lamina. The preparations were examined under ×20 magnification.

Techniques Used: Staining

Effect of nifedipine on the phosphorylation and protein level of MEK 1/2 in rat VSMC. (A) The phosphorylation or protein level of MEK 1/2 was detected by immunoblot analysis using antibody phosphospecific or specific for MEK 1/2, as described in Methods. p-MEK 1/2 or MEK 1/2 shows the phosphorylation or the protein level of MEK 1/2, respectively. (B) The quantitation of the phosphorylated MEK 1/2 from three separate experiments is shown, and each bar represents the mean±s.e.mean. * P
Figure Legend Snippet: Effect of nifedipine on the phosphorylation and protein level of MEK 1/2 in rat VSMC. (A) The phosphorylation or protein level of MEK 1/2 was detected by immunoblot analysis using antibody phosphospecific or specific for MEK 1/2, as described in Methods. p-MEK 1/2 or MEK 1/2 shows the phosphorylation or the protein level of MEK 1/2, respectively. (B) The quantitation of the phosphorylated MEK 1/2 from three separate experiments is shown, and each bar represents the mean±s.e.mean. * P

Techniques Used: Quantitation Assay

5) Product Images from "Cathepsin-L, a Key Molecule in the Pathogenesis of Drug-Induced and I-Cell Disease-Mediated Gingival Overgrowth "

Article Title: Cathepsin-L, a Key Molecule in the Pathogenesis of Drug-Induced and I-Cell Disease-Mediated Gingival Overgrowth

Journal: The American Journal of Pathology

doi:

Dose-dependent suppression of cathepsin-L activity in gingival fibroblasts cultured with nifedipine. Gingival fibroblasts were cultured with or without various doses of nifedipine for the indicated time periods. Cathepsin activity was measured as described in Materials and Methods. Since a specific substrate for cathepsin-L is not available, combined activity of cathepsin-(B+L) ( A ) and cathepsin-B activity ( B ) was measured. Data are representative of the results obtained from gingival fibroblasts isolated from normal gingival tissues and nifedipine-induced gingival overgrowth, since gingival fibroblasts obtained from nifedipine-induced gingival overgrowth and from normal tissues were similarly affected by nifedipine. Values are expressed as the % activity against that of controls (day 0).
Figure Legend Snippet: Dose-dependent suppression of cathepsin-L activity in gingival fibroblasts cultured with nifedipine. Gingival fibroblasts were cultured with or without various doses of nifedipine for the indicated time periods. Cathepsin activity was measured as described in Materials and Methods. Since a specific substrate for cathepsin-L is not available, combined activity of cathepsin-(B+L) ( A ) and cathepsin-B activity ( B ) was measured. Data are representative of the results obtained from gingival fibroblasts isolated from normal gingival tissues and nifedipine-induced gingival overgrowth, since gingival fibroblasts obtained from nifedipine-induced gingival overgrowth and from normal tissues were similarly affected by nifedipine. Values are expressed as the % activity against that of controls (day 0).

Techniques Used: Activity Assay, Cell Culture, Isolation

The effects of TG on the activity of cathepsins. Gingival fibroblasts were cultured with or without 100 ng/ml of nifedipine in the presence or absence of the indicated concentrations of Ca mobilizer TG. Twenty-four hours later, cellular proteins were extracted and were subjected to enzyme assay. TG suppressed both cathepsin-(B+L) and -B activity, while nifedipine alone specifically suppressed cathepsin-(B+L) activity. Values are expressed as the % activity against that of controls (day 0).
Figure Legend Snippet: The effects of TG on the activity of cathepsins. Gingival fibroblasts were cultured with or without 100 ng/ml of nifedipine in the presence or absence of the indicated concentrations of Ca mobilizer TG. Twenty-four hours later, cellular proteins were extracted and were subjected to enzyme assay. TG suppressed both cathepsin-(B+L) and -B activity, while nifedipine alone specifically suppressed cathepsin-(B+L) activity. Values are expressed as the % activity against that of controls (day 0).

Techniques Used: Activity Assay, Cell Culture, Enzymatic Assay

mRNA expression of various lysosomal enzymes cultured with or without nifedipine in gingival fibroblasts. The expressions of mRNA encoding various lysosomal enzymes were examined in gingival fibroblasts cultured with (nifedipine) or without (−) 100 ng/ml of nifedipine for the indicated time periods. Total RNA was isolated and was subjected to RT-PCR analysis as described in Materials and Methods. Values are representative of the results obtained from several gingival fibroblasts from different donors, since all cells tested showed similar results. Expression of cathepsin-L mRNA was markedly suppressed in gingival fibroblasts after 1 day of incubation with nifedipine, while that of other lysosomal enzymes was not apparently influenced. HeLa cells served as the positive control.
Figure Legend Snippet: mRNA expression of various lysosomal enzymes cultured with or without nifedipine in gingival fibroblasts. The expressions of mRNA encoding various lysosomal enzymes were examined in gingival fibroblasts cultured with (nifedipine) or without (−) 100 ng/ml of nifedipine for the indicated time periods. Total RNA was isolated and was subjected to RT-PCR analysis as described in Materials and Methods. Values are representative of the results obtained from several gingival fibroblasts from different donors, since all cells tested showed similar results. Expression of cathepsin-L mRNA was markedly suppressed in gingival fibroblasts after 1 day of incubation with nifedipine, while that of other lysosomal enzymes was not apparently influenced. HeLa cells served as the positive control.

Techniques Used: Expressing, Cell Culture, Isolation, Reverse Transcription Polymerase Chain Reaction, Incubation, Positive Control

Latent and active cathepsin activity of cells cultured with or without nifedipine. Enzyme activities of active forms of cathepsin-(B+L) ( A ), active form of cathepsin-B ( B ), total forms of cathepsin-(B+L) ( C ), and total form of cathepsin-B ( D ) were measured in gingival fibroblasts cultured with or without 100 ng/ml of nifedipine. Gingival fibroblasts cultured with or without nifedipine were subjected to measurement of cathepsin activities as described in Materials and Methods. Values are representative of the results obtained from gingival fibroblasts isolated from normal gingival tissues and nifedipine-induced gingival overgrowth, since gingival fibroblasts obtained from nifedipine-induced gingival overgrowth and from normal tissues were similarly affected by nifedipine. Values are expressed as the % activity against that of controls (day 0). Both active and total forms of cathepsin-(B+L) activity were significantly suppressed by nifedipine, while that of cathepsin-B was not influenced.
Figure Legend Snippet: Latent and active cathepsin activity of cells cultured with or without nifedipine. Enzyme activities of active forms of cathepsin-(B+L) ( A ), active form of cathepsin-B ( B ), total forms of cathepsin-(B+L) ( C ), and total form of cathepsin-B ( D ) were measured in gingival fibroblasts cultured with or without 100 ng/ml of nifedipine. Gingival fibroblasts cultured with or without nifedipine were subjected to measurement of cathepsin activities as described in Materials and Methods. Values are representative of the results obtained from gingival fibroblasts isolated from normal gingival tissues and nifedipine-induced gingival overgrowth, since gingival fibroblasts obtained from nifedipine-induced gingival overgrowth and from normal tissues were similarly affected by nifedipine. Values are expressed as the % activity against that of controls (day 0). Both active and total forms of cathepsin-(B+L) activity were significantly suppressed by nifedipine, while that of cathepsin-B was not influenced.

Techniques Used: Activity Assay, Cell Culture, Isolation

Related Articles

other:

Article Title: Cathepsin-L, a Key Molecule in the Pathogenesis of Drug-Induced and I-Cell Disease-Mediated Gingival Overgrowth
Article Snippet: The blocker of L-type Ca (2+) channels, nifedipine, was from Bayer AG Pharma Research Center (Wuppertal, Germany).

Article Title: Interaction of Dihydropyridine Calcium Channel Agonists and Antagonists with Adenosine Receptors
Article Snippet: Methyl 2,6-dimethyl-5-nitro-4-(2-trifluoromethylphenyl) 1,4-dihydropyridine-3-carboxylate, Bay K 8644, and nifedipine were from Bayer AG.

Article Title: Effects of nicorandil as compared to mixtures of sodium nitroprusside and levcromakalim in isolated rat aorta
Article Snippet: The following drugs were used: sodium nitroprusside, glibenclamide, acetylcholine chloride and noradrenaline (Sigma Chemical, Madrid, Spain), nicorandil (Merck Farma y Química, Barcelona, Spain), 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ, Tocris Cookson, Bristol, U.K.), levcromakalim (Smith Kline Beecham Pharmaceuticals) and nifedipine (Bayer AG, Leverkusen, Germany).

Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 92
    Bayer AG nifedipine
    Displacement by <t>nifedipine</t> of [ 3 H]-R-PIA and [ 3 H]-XAC bound to membrane receptors. Open symbols [ 3 H]-R-PIA binding (K i app. 4.15 ± 1.37 × 10 −6 , B max app. 653 fmol/mg protein); closed symbols [ 3 H]-XAC (K i app. 1.86 ± 0.42 × 10 −6 M, B max app. 868 fmol/mg protein).
    Nifedipine, supplied by Bayer AG, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/nifedipine/product/Bayer AG
    Average 92 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    nifedipine - by Bioz Stars, 2021-01
    92/100 stars
      Buy from Supplier

    88
    Bayer AG m nifedipine
    Representative traces of single N-channel activity recorded from cell-attached patches of control NG108-15 and cav1(+) cells. ( A ) Traces from a control NG108-15 cell obtained with pulses from −40 to +20 mV of 180 ms each. The averaged current at the bottom (−0.051 pA) was calculated over 257 sweeps including nulls. ( B ) Traces from a cav1(+) cell. The averaged current at the bottom is 69% smaller (−0.016 pA) than control (423 sweeps including nulls). The patch pipette contained 100 mM Ba 2+ and the L-type Ca 2+ channel blocker <t>nifedipine</t> (10 μ M).
    M Nifedipine, supplied by Bayer AG, used in various techniques. Bioz Stars score: 88/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/m nifedipine/product/Bayer AG
    Average 88 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    m nifedipine - by Bioz Stars, 2021-01
    88/100 stars
      Buy from Supplier

    90
    Bayer AG nifedipine controlled release tablet
    Mean (standard deviation) plasma concentration-time profiles of <t>nifedipine</t> following a single oral administration of 30 mg nifedipine alone or in combination with 750 mg apatinib in patients with advanced solid tumors.
    Nifedipine Controlled Release Tablet, supplied by Bayer AG, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/nifedipine controlled release tablet/product/Bayer AG
    Average 90 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    nifedipine controlled release tablet - by Bioz Stars, 2021-01
    90/100 stars
      Buy from Supplier

    Image Search Results


    Displacement by nifedipine of [ 3 H]-R-PIA and [ 3 H]-XAC bound to membrane receptors. Open symbols [ 3 H]-R-PIA binding (K i app. 4.15 ± 1.37 × 10 −6 , B max app. 653 fmol/mg protein); closed symbols [ 3 H]-XAC (K i app. 1.86 ± 0.42 × 10 −6 M, B max app. 868 fmol/mg protein).

    Journal: Pharmacology & toxicology

    Article Title: Interaction of Dihydropyridine Calcium Channel Agonists and Antagonists with Adenosine Receptors

    doi:

    Figure Lengend Snippet: Displacement by nifedipine of [ 3 H]-R-PIA and [ 3 H]-XAC bound to membrane receptors. Open symbols [ 3 H]-R-PIA binding (K i app. 4.15 ± 1.37 × 10 −6 , B max app. 653 fmol/mg protein); closed symbols [ 3 H]-XAC (K i app. 1.86 ± 0.42 × 10 −6 M, B max app. 868 fmol/mg protein).

    Article Snippet: Methyl 2,6-dimethyl-5-nitro-4-(2-trifluoromethylphenyl) 1,4-dihydropyridine-3-carboxylate, Bay K 8644, and nifedipine were from Bayer AG.

    Techniques: Binding Assay

    Representative measurements of the migration of circulating progenitor cells (CPCs) labeled with DAPI by fluorescence in a patient treated with eplerenone, a patient treated with nifedipine, and a patient treated with losartan before the beginning of treatment (0 weeks) and after 4, 12, and 48 weeks of treatment (top). Comparison of the migration of CPCs in patients in the eplerenone, nifedipine, and losartan groups before the beginning of treatment (0 weeks) and after 4, 12, and 48 weeks of treatment (bottom). * P

    Journal: Clinical pharmacology and therapeutics

    Article Title: Mineralocorticoid Receptor Blocker Eplerenone Improves Endothelial Function and Inhibits Rho-Associated Kinase Activity in Patients With Hypertension

    doi: 10.1038/clpt.2011.227

    Figure Lengend Snippet: Representative measurements of the migration of circulating progenitor cells (CPCs) labeled with DAPI by fluorescence in a patient treated with eplerenone, a patient treated with nifedipine, and a patient treated with losartan before the beginning of treatment (0 weeks) and after 4, 12, and 48 weeks of treatment (top). Comparison of the migration of CPCs in patients in the eplerenone, nifedipine, and losartan groups before the beginning of treatment (0 weeks) and after 4, 12, and 48 weeks of treatment (bottom). * P

    Article Snippet: A total of 60 patients with essential hypertension were randomized to blinded treatment with eplerenone (Pfizer Pharmaceutical, Tokyo, Japan; n = 20; 15 men and 5 women; mean age, 54 ± 10 years) at a dose of 50 mg, nifedipine (Bayer Pharmaceutical, Osaka, Japan; n = 20; 15 men and 5 women; mean age, 55 ± 11 years) at a dose of 40 mg, or losartan potassium (Banyu Pharmaceutical, Tokyo, Japan; n = 20; 15 men and 5 women; mean age, 53 ± 9 years) at a dose of 100 mg once daily in the morning, during a 48-week active treatment period.

    Techniques: Migration, Labeling, Fluorescence

    Representative measurements of the number of circulating progenitor cells (CPCs) by flow cytometry in a patient treated with eplerenone, a patient treated with nifedipine, and a patient treated with losartan before the beginning of treatment (0 weeks) and after 4, 12, and 48 weeks of treatment (top). Comparison of the number of CPCs in patients in the eplerenone, nifedipine, and losartan groups before the beginning of treatment (0 weeks) and after 4, 12, and 48 weeks of treatment (bottom). * P

    Journal: Clinical pharmacology and therapeutics

    Article Title: Mineralocorticoid Receptor Blocker Eplerenone Improves Endothelial Function and Inhibits Rho-Associated Kinase Activity in Patients With Hypertension

    doi: 10.1038/clpt.2011.227

    Figure Lengend Snippet: Representative measurements of the number of circulating progenitor cells (CPCs) by flow cytometry in a patient treated with eplerenone, a patient treated with nifedipine, and a patient treated with losartan before the beginning of treatment (0 weeks) and after 4, 12, and 48 weeks of treatment (top). Comparison of the number of CPCs in patients in the eplerenone, nifedipine, and losartan groups before the beginning of treatment (0 weeks) and after 4, 12, and 48 weeks of treatment (bottom). * P

    Article Snippet: A total of 60 patients with essential hypertension were randomized to blinded treatment with eplerenone (Pfizer Pharmaceutical, Tokyo, Japan; n = 20; 15 men and 5 women; mean age, 54 ± 10 years) at a dose of 50 mg, nifedipine (Bayer Pharmaceutical, Osaka, Japan; n = 20; 15 men and 5 women; mean age, 55 ± 11 years) at a dose of 40 mg, or losartan potassium (Banyu Pharmaceutical, Tokyo, Japan; n = 20; 15 men and 5 women; mean age, 53 ± 9 years) at a dose of 100 mg once daily in the morning, during a 48-week active treatment period.

    Techniques: Flow Cytometry, Cytometry

    Representative data from western blot analysis for phospho-myosin-binding subunit (p-MBS), total-myosin-binding subunit (t-MBS), and β tublin in a patient treated with eplerenone, a patient treated with nifedipine, and a patient treated with losartan before the beginning of treatment (0 weeks) and after 4, 12, and 48 weeks of treatment (top). ROCK activity (p-MBS/t-MBS) in patients in the eplerenone, nifedipine, and losartan groups before the beginning of treatment (0 weeks) and after 4, 12, and 48 weeks of treatment (bottom). * P

    Journal: Clinical pharmacology and therapeutics

    Article Title: Mineralocorticoid Receptor Blocker Eplerenone Improves Endothelial Function and Inhibits Rho-Associated Kinase Activity in Patients With Hypertension

    doi: 10.1038/clpt.2011.227

    Figure Lengend Snippet: Representative data from western blot analysis for phospho-myosin-binding subunit (p-MBS), total-myosin-binding subunit (t-MBS), and β tublin in a patient treated with eplerenone, a patient treated with nifedipine, and a patient treated with losartan before the beginning of treatment (0 weeks) and after 4, 12, and 48 weeks of treatment (top). ROCK activity (p-MBS/t-MBS) in patients in the eplerenone, nifedipine, and losartan groups before the beginning of treatment (0 weeks) and after 4, 12, and 48 weeks of treatment (bottom). * P

    Article Snippet: A total of 60 patients with essential hypertension were randomized to blinded treatment with eplerenone (Pfizer Pharmaceutical, Tokyo, Japan; n = 20; 15 men and 5 women; mean age, 54 ± 10 years) at a dose of 50 mg, nifedipine (Bayer Pharmaceutical, Osaka, Japan; n = 20; 15 men and 5 women; mean age, 55 ± 11 years) at a dose of 40 mg, or losartan potassium (Banyu Pharmaceutical, Tokyo, Japan; n = 20; 15 men and 5 women; mean age, 53 ± 9 years) at a dose of 100 mg once daily in the morning, during a 48-week active treatment period.

    Techniques: Western Blot, Binding Assay, Activity Assay

    Representative traces of single N-channel activity recorded from cell-attached patches of control NG108-15 and cav1(+) cells. ( A ) Traces from a control NG108-15 cell obtained with pulses from −40 to +20 mV of 180 ms each. The averaged current at the bottom (−0.051 pA) was calculated over 257 sweeps including nulls. ( B ) Traces from a cav1(+) cell. The averaged current at the bottom is 69% smaller (−0.016 pA) than control (423 sweeps including nulls). The patch pipette contained 100 mM Ba 2+ and the L-type Ca 2+ channel blocker nifedipine (10 μ M).

    Journal: Biophysical Journal

    Article Title: Caveolin-1 Expression and Membrane Cholesterol Content Modulate N-Type Calcium Channel Activity in NG108-15 Cells

    doi: 10.1529/biophysj.105.065623

    Figure Lengend Snippet: Representative traces of single N-channel activity recorded from cell-attached patches of control NG108-15 and cav1(+) cells. ( A ) Traces from a control NG108-15 cell obtained with pulses from −40 to +20 mV of 180 ms each. The averaged current at the bottom (−0.051 pA) was calculated over 257 sweeps including nulls. ( B ) Traces from a cav1(+) cell. The averaged current at the bottom is 69% smaller (−0.016 pA) than control (423 sweeps including nulls). The patch pipette contained 100 mM Ba 2+ and the L-type Ca 2+ channel blocker nifedipine (10 μ M).

    Article Snippet: All experiments in cell-attached patches were carried out with the recording pipette containing 100 mM Ba2+ and 10 μ M nifedipine.

    Techniques: Activity Assay, Mass Spectrometry, Transferring

    Mean (standard deviation) plasma concentration-time profiles of nifedipine following a single oral administration of 30 mg nifedipine alone or in combination with 750 mg apatinib in patients with advanced solid tumors.

    Journal: Drug Design, Development and Therapy

    Article Title: Effects of Apatinib on the Pharmacokinetics of Nifedipine and Warfarin in Patients with Advanced Solid Tumors

    doi: 10.2147/DDDT.S237301

    Figure Lengend Snippet: Mean (standard deviation) plasma concentration-time profiles of nifedipine following a single oral administration of 30 mg nifedipine alone or in combination with 750 mg apatinib in patients with advanced solid tumors.

    Article Snippet: The patients received a single oral dose of 30 mg nifedipine controlled-release tablet (30 mg/tablet, Bayer Healthcare AG, Leverkusen, Germany) on days 1/14 and a single oral dose of 3 mg warfarin tablet (3 mg/tablet, Orion Corporation, Espoo, Finland) on days 3/16.

    Techniques: Standard Deviation, Concentration Assay